COUR Pharma raises $50 million for type 1 diabetes push

19 June 2026

US biotech COUR Pharma has closed a $50 million series B financing round to advance CNP-103, its experimental type 1 diabetes therapy designed to address the autoimmune cause of the disease rather than simply help manage blood glucose.

The round was led by Lumira Ventures and Roche Venture Fund, with new backing from French pharma Sanofi (Euronext: SAN). Existing investors Alpha Wave Ventures, Pfizer Ventures, Angelini Ventures and T1D Fund: A Breakthrough T1D Venture also joined the financing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK